CN1045005C - 双噁二唑烷衍生物,含该化合物的药物组合物及其用途 - Google Patents

双噁二唑烷衍生物,含该化合物的药物组合物及其用途 Download PDF

Info

Publication number
CN1045005C
CN1045005C CN94191963A CN94191963A CN1045005C CN 1045005 C CN1045005 C CN 1045005C CN 94191963 A CN94191963 A CN 94191963A CN 94191963 A CN94191963 A CN 94191963A CN 1045005 C CN1045005 C CN 1045005C
Authority
CN
China
Prior art keywords
bis
group
internal standard
phenoxy
nmr spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94191963A
Other languages
English (en)
Chinese (zh)
Other versions
CN1122133A (zh
Inventor
新形邦宏
高桥工
丸山龙也
铃木贵之
前野恭一
恩田健一
绀谷彻
野城修
小池礼子
岛谷彰良
入江润
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN1122133A publication Critical patent/CN1122133A/zh
Application granted granted Critical
Publication of CN1045005C publication Critical patent/CN1045005C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN94191963A 1993-04-30 1994-04-26 双噁二唑烷衍生物,含该化合物的药物组合物及其用途 Expired - Fee Related CN1045005C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP12789893 1993-04-30
JP127898/93 1993-04-30
JP35020993 1993-12-29
JP350209/93 1993-12-29

Publications (2)

Publication Number Publication Date
CN1122133A CN1122133A (zh) 1996-05-08
CN1045005C true CN1045005C (zh) 1999-09-08

Family

ID=26463731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94191963A Expired - Fee Related CN1045005C (zh) 1993-04-30 1994-04-26 双噁二唑烷衍生物,含该化合物的药物组合物及其用途

Country Status (14)

Country Link
US (1) US5643931A (enExample)
EP (1) EP0696585B1 (enExample)
CN (1) CN1045005C (enExample)
AT (1) ATE174593T1 (enExample)
AU (1) AU680496B2 (enExample)
CA (1) CA2160989A1 (enExample)
DE (1) DE69415314T2 (enExample)
DK (1) DK0696585T3 (enExample)
ES (1) ES2129123T3 (enExample)
GR (1) GR3029428T3 (enExample)
HU (1) HUT73431A (enExample)
RU (1) RU2135487C1 (enExample)
TW (1) TW401418B (enExample)
WO (1) WO1994025448A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244542C (zh) * 1996-12-24 2006-03-08 中外制药株式会社 具有nos抑制作用的芳香族胺衍生物
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
US6534037B1 (en) 1998-01-21 2003-03-18 Neorx Corporation Non-steroidal compounds for steroid receptors and uses relating thereto
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7608639B2 (en) 2003-10-14 2009-10-27 Eli Lilly And Company Phenoxyether derivatives as PPAR modulators
TW200815377A (en) * 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
TW200932219A (en) * 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
EP2332528A1 (de) * 2009-12-14 2011-06-15 Grünenthal GmbH Substituierte aromatische Dicarbonsäureamide als Arzneimittel
KR101661825B1 (ko) * 2011-08-03 2016-09-30 내셔널 타이완 유니버시티 Ｓｒｃ 상동성-2 함유 단백질 티로신 포스파타제-1의 작용물질 및 그를 사용한 치료방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003425A1 (en) * 1990-08-23 1992-03-05 Pfizer Inc. Hypoglycemic hydroxyurea derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4598153A (en) * 1984-12-19 1986-07-01 The United States Of America As Represented By The Department Of Health And Human Services Metaphit, a specific acylating agent for the [3 H] phencyclidine
JP3176063B2 (ja) * 1991-04-17 2001-06-11 ファルマシア・アンド・アップジョン・カンパニー 新規中枢神経作用性置換フェニルアザシクロアルカン類
US5508296A (en) * 1991-07-30 1996-04-16 Yamanouchi Pharmaceutical Co., Ltd. Bisheterocyclic derivative or salt thereof
WO1993009106A1 (fr) * 1991-10-28 1993-05-13 Tsentr Po Khimii Lekarstvennykh Sredstv Derives de 5-phenoxymethyle-1,2,4-oxadiazole, leur sels, procede d'obtention et preparation pharmaceutique a base de ceux-ci presentant des proprietes antihypertensives, antiangineuses, antiarrhythmiques et antiglaucomatomeuses
US5420146A (en) * 1994-05-10 1995-05-30 American Home Products Corporation Di-oxadiazolidine derivatives as antihyperglycemic agents
JPH09303021A (ja) * 1996-05-17 1997-11-25 Matsushita Electric Works Ltd 近接型ワイヤレス電気錠制御システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003425A1 (en) * 1990-08-23 1992-03-05 Pfizer Inc. Hypoglycemic hydroxyurea derivatives

Also Published As

Publication number Publication date
US5643931A (en) 1997-07-01
EP0696585A1 (en) 1996-02-14
CN1122133A (zh) 1996-05-08
DE69415314T2 (de) 1999-05-20
AU680496B2 (en) 1997-07-31
DK0696585T3 (da) 1999-08-23
ES2129123T3 (es) 1999-06-01
WO1994025448A1 (fr) 1994-11-10
EP0696585B1 (en) 1998-12-16
DE69415314D1 (de) 1999-01-28
HU9503090D0 (en) 1995-12-28
AU6582394A (en) 1994-11-21
HUT73431A (en) 1996-07-29
ATE174593T1 (de) 1999-01-15
RU2135487C1 (ru) 1999-08-27
EP0696585A4 (enExample) 1996-03-27
GR3029428T3 (en) 1999-05-28
TW401418B (en) 2000-08-11
CA2160989A1 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1024667C (zh) 取代的氨甲基四氢化萘和取化氨甲基氢化苯并吡喃及其盐制备方法
CN1166633C (zh) 新的α-氨基酸磺酰基化合物、其制备方法和含有它们的药物组合物
CN1184215C (zh) 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物
HK1043365A1 (en) N-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
CN1045005C (zh) 双噁二唑烷衍生物,含该化合物的药物组合物及其用途
CN1671659A (zh) 新的取代吲哚
CN1617850A (zh) 二苄胺化合物及其药物用途
CN1272107A (zh) 作为因子Xa抑制剂的苄脒衍生物
CN1261419C (zh) 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮及其抑制激素敏感性脂酶的用途
CN87101285A (zh) 8-取代的-2-氨基-1，2，3，4-四氢化荼
CN1390196A (zh) 具有药理活性的新的二羧酸衍生物
CN1589258A (zh) 新的β－苯基－α－氧取代的丙酸衍生物,它的制备方法和它们制备药学上重要的化合物的应用
CN1252068A (zh) 3－哌啶基－4－氧基喹唑啉衍生物和含有该化合物的药物组合物
CN1027069C (zh) 噁唑烷二酮衍生物的制造方法
CN88101620A (zh) 苯基三唑衍生物和杀虫剂
CN100351245C (zh) 二唑和噻二唑及其作为金属蛋白酶抑制剂的用途
CN1011780B (zh) 苯氧基乙酸衍生物的制备方法
CN1211374C (zh) 新的杂环衍生物、其制备方法和包含它们的药物组合物
CN1152879C (zh) 萘啶衍生物
CN1516695A (zh) 用作抗病毒剂的芳基磺酰胺类化合物
CN1852901A (zh) 有机化合物
CN86104787A (zh) 制备聚-4-氨基吡咯-2-甲酰胺基衍生物的方法
CN1019388B (zh) 新型n-烷磺酰苯胺衍生物的制备方法
CN1976901A (zh) 新的芳脒衍生物、其盐、及含有这些的抗真菌剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee